The DASciS Software for BSI Calculation as a Valuable Prognostic Tool in mCRPC Treated with 223RaCl2: A Multicenter...

Area of Science:

• Nuclear medicine
• Oncology
• Radiopharmaceuticals

Background:

• Metastatic castration-resistant prostate cancer (mCRPC) with bone metastases is a significant clinical challenge.
• Radium-223 dichloride (²²³RaCl₂) offers a therapeutic option for mCRPC patients.
• Identifying prognostic factors for ²²³RaCl₂ treatment is crucial.

Purpose of the Study:

• To evaluate the impact of baseline bone scan index (BSI) on overall survival (OS) in mCRPC patients receiving ²²³RaCl₂.
• To assess the utility of the DASciS software for standardized BSI calculation across multiple centers.

Main Methods:

• Retrospective analysis of 370 pre-treatment bone scans (BS) from mCRPC patients.
• BSI calculated using the DASciS software across six Italian Nuclear Medicine Units.
• Statistical analysis incorporating BSI and other clinical variables (Gleason score, Hb, tALP, PSA) to predict OS.

Main Results:

• Median OS was 13 months for patients treated with ²²³RaCl₂.
• Baseline BSI was a significant independent risk factor for OS in univariate analysis (HR 1.137, p=0.001).
• Baseline BSI remained a statistically significant predictor of OS in multivariate analysis (HR 1.054, p<0.001), even after adjusting for other clinical factors.

Conclusions:

• Baseline BSI is a significant predictor of overall survival in mCRPC patients treated with ²²³RaCl₂.
• Higher baseline BSI correlates with worse OS.
• The DASciS software is an effective and efficient tool for BSI calculation in multicenter studies.